Latest Conference Articles

The time to definitive deterioration was delayed among patients receiving trastuzumab deruxtecan vs treatment of physician’s choice in all prespecified scales in DESTINY-Breast02.

Patient-reported outcomes demonstrated a manageable safety profile with abemaciclib.

AnnMarie Walton, PhD, MPH, RN, OCN, CHES, FAAN, discusses her research on plastic-backed pads and discusses the importance of better methods to reduce exposure to antineoplastic drug residue.

Enzalutamide plus leuprolide lowered the risk of metastases or death by 58% compared with placebo plus leuprolide.

Apalutamide plus androgen deprivation therapy (ADT) yielded a progression-free survival of 24.5 months vs 21.0 months with ADT alone.

Sarah Low RN, MSN, OCN, CMSRN; and Claudia Maldonado-Howell, RN, MSN, FNP, BS, CMSRN, discuss their research on wearable technology.

Heather Niccum Haag, BSN, RN, CCRN, shares her experience creating an educational resource for her patients with Von-Hippel Lindau tumors who are receiving belzutifan.

A database analysis showed that zoledronic acid led to a 64% reduction in fracture risk among patients with metastatic hormone-sensitive prostate cancer.

Nivolumab bested placebo in improving disease-free survival rates in patients with muscle-invasive urothelial carcinoma and muscle-invasive bladder cancer.

Elizabeth Loach, MSN, APRN, CNS, AGCNS-BC, OCN, discusses the importance of including frontline nurses in nursing leadership task forces.

The Splashblocker was found to be an effective way to reduce contaminated particles. Plastic backed pads had mixed reviews.

Findings from a real-world, retrospective analysis support the use of apalutamide for the prostate-specific antigen reduction among patients with metastatic castration-sensitive prostate cancer.

Oncology nurse investigators from Dana-Farber discuss the value of weighted blankets in reducing patient anxiety during infusions.

Data presented during the ONS Annual Congress offers guidance for nurses caring for patients receiving darolutamide, docetaxel, and androgen deprivation therapy.

Jessica MacIntyre, DNP, MBA, APRN, NP-C, AOCNP, discusses ways to standardize the process of referring patients to the Leukemia and Lymphoma Society.

Rita Deimler, MSN, ANP-BC, outlines best cardiac event monitoring and management practices for patients receiving the CDK4/6 inhibitor ribociclib.

Acknowledging and addressing maladaptive coping mechanisms may help reduce moral distress and burnout among oncology nurses.

Stephanie Jackson, DNP, MSN, RN, AOCNS, BMTCN, highlights how her unit leveraged an educational video to improve compliance with double verification for high-alert medications.

Eric Zack, DNP, RN, ACNP-BC, AOCN, BMTCN, describes disseminated intravascular coagulation and best nursing strategies to mitigate the severity of this condition.

Elizabeth R. Cullen, MSN, ARNP, highlights the efficacy of avasopasem manganese in mitigating severe oral mucositis in patients with locally advanced head and neck cancer.

Managing ocular-related adverse effects with mirvetuximab soravtansine is key to helping patients with ovarian cancer stay on treatment.

An analysis of the cilta-cel safety profile yielded promising results, according to nurse investigators.

Victoria R. Crowder, BSN, RN, and co-investigators, highlight existing gaps in the understanding of malnutrition risks facing patients with acute myeloid leukemia and myelodysplastic syndromes.

Donna Catamero, ANP-BC, OCN, CCRC, outlines best management strategies for treating patients receiving teclistamab who experience cytokine release syndrome.

Monitoring patients for cytokine release syndrome is a key aspect of caring for patients receiving teclistamab.

Ashley Marenyi, RN, BSN, OCN, highlights the importance of counseling patients with head and neck cancer on the short-term and long-term adverse effects of radiation treatment.

Specialists highlight the best practices and latest treatment regimens for patients presenting with myelofibrosis, polycythemia vera, and essential thrombocythemia.

Combined adjuvant treatment with mRNA-4157 in combination with pembrolizumab improved recurrence rates in patients with resected high-risk melanoma.